Phase II Study of Granulocyte-Macrophage Colony Stimulating Factor Plus Mitoxantrone for the Treatment of Hormone Refractory Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Mitoxantrone; Sargramostim
- Indications Prostate cancer
- Focus Therapeutic Use
- 23 Oct 2017 Status changed from active, no longer recruiting to discontinued.
- 10 Jun 2017 Biomarkers information updated
- 03 Jul 2012 Actual patient number is 10 according to ClinicalTrials.gov.